Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600mg/m2 in recurrent ovarian cancer

被引:12
作者
Pendlebury, Adam [1 ]
DeBernardo, Robert [1 ]
Rose, Peter G. [1 ]
机构
[1] Cleveland Clin, Taussig Canc Ctr, 9500 Euclid Ave,A81, Cleveland, OH 44195 USA
关键词
cardiotoxicity; gynecologic malignancy; long-term chemotherapy; pegylated liposomal doxorubicin; safety; RANDOMIZED PHASE-III; EPITHELIAL OVARIAN; GYNECOLOGIC MALIGNANCIES; CARDIAC SURVEILLANCE; CARCINOMA; PLD; CARDIOTOXICITY; CHEMOTHERAPY; FAILURE; TRIAL;
D O I
10.1097/CAD.0000000000000521
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pegylated liposomal doxorubicin (PLD) is used widely in gynecologic oncology and other oncology disciplines. Native doxorubicin use is associated with the potential for significant toxicity. Cardiac toxicity in particular limits lifetime dose. PLD has not been shown to be associated with clinical cardiac toxicity. We report on the long-term use of PLD in a patient with recurrent high-grade serous ovarian cancer to a lifetime dose of 4600mg/m(2). This therapy was associated with long-term stable disease, good performance status, and minimal adverse effects.
引用
收藏
页码:815 / 817
页数:3
相关论文
共 20 条
  • [1] Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)
    Alberts, David S.
    Liu, P. Y.
    Wilczynski, Sharon P.
    Clouser, Mary C.
    Lopez, Ana Maria
    Michelin, David P.
    Lanzotti, Victor J.
    Markman, Maurie
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 108 (01) : 90 - 94
  • [2] Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®):: Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer
    Andreopoulou, E.
    Gaiotti, D.
    Kim, E.
    Downey, A.
    Mirchandani, D.
    Hamilton, A.
    Jacobs, Allan
    Curtin, John
    Muggia, F.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (04) : 716 - 721
  • [3] The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin
    Berry, G
    Billingham, M
    Alderman, E
    Richardson, P
    Torti, F
    Lum, B
    Patek, A
    Martin, FJ
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (07) : 711 - 716
  • [4] Squamous Cell Carcinoma of the Oral Cavity in Nonsmoking Women: A New and Unusual Complication of Chemotherapy for Recurrent Ovarian Cancer?
    Cannon, Timothy L.
    Lai, Dominic W.
    Hirsch, David
    Delacure, Mark
    Downey, Andrea
    Kerr, Alexander R.
    Bannan, Michael
    Andreopoulou, Eleni
    Safra, Tamar
    Muggia, Franco
    [J]. ONCOLOGIST, 2012, 17 (12) : 1541 - 1546
  • [5] Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: Is it necessary?
    Gill, Sarah E.
    Savage, Kari
    Wysham, Weiya Z.
    Blackhurst, Dawn W.
    Winter, William E.
    Puls, Larry E.
    [J]. GYNECOLOGIC ONCOLOGY, 2013, 129 (03) : 544 - 547
  • [6] Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
    Gordon, AN
    Fleagle, JT
    Guthrie, D
    Parkin, DE
    Gore, ME
    Lacave, AJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) : 3312 - 3322
  • [7] Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
    Grenader, Tal
    Goldberg, Anthony
    Gabizon, Alberto
    [J]. ANTI-CANCER DRUGS, 2010, 21 (09) : 868 - 871
  • [8] High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies
    Kesterson, Joshua P.
    Odunsi, Kunle
    Lele, Shashikant
    [J]. CHEMOTHERAPY, 2010, 56 (02) : 108 - 111
  • [9] Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD)
    Kushnir, C. L.
    Angarita, A. M.
    Havrilesky, L. J.
    Thompson, S.
    Spahlinger, D.
    Sinno, A. K.
    Tanner, E. J.
    Secord, A. A.
    Roche, K. L.
    Stone, R. L.
    Fader, A. N.
    [J]. GYNECOLOGIC ONCOLOGY, 2015, 137 (03) : 503 - 507
  • [10] Michener CM, 2005, ONCOLOGY-NY, V19, P1277